Rubicon Research Limited announced key decisions made during its Board of Directors meeting held on February 3, 2026. The board approved the appointment of Dr. Pradnya Saravade as Additional - Independent Woman Director for a period of three years, effective February 3, 2026, to February 2, 2029, subject to member approval. Additionally, the resignation of Mr. Anand Agarwal as a Non-Executive Director, nominated by General Atlantic Singapore RR Pte Ltd, was noted, effective from the close of business on February 3, 2026. The Board also approved and recommended the appointment of M/s. BNP & Associates as the Secretarial Auditor for FY 2025-26 and for the subsequent four years until FY 2029-30, pending member approval. Furthermore, the board granted in-principle approval for the merger of KIA Health Tech Private Limited, a wholly owned subsidiary, with Rubicon Research Limited. This merger is subject to board approval of the scheme of arrangement, regulatory approvals, and other administrative formalities. The net worth of KIA Health Tech was ₹815.80 Lakhs with Nil revenue, while Rubicon Research had a net worth of ₹66,778.57 Lakhs and total revenue of ₹1,09,352.40 Lakhs as of March 31, 2025. The rationale for the merger is to achieve operational synergies. The meeting commenced at 3:00 PM IST and concluded at 4:30 PM IST.
